/images/ppid_59c68470-image-176865003115368906.webp)
/images/ppid_59c68470-image-176848503737660487.webp)
/images/ppid_a911dc6a-image-176856162801360067.webp)
What is the story about?
Mumbai-based Indian specialty chemical maker Rossari Biotech Ltd. reported its earnings for the third quarter on Saturday, January 17.
While its net profit, revenue and earnings before interest tax depreciation and amortisation (EBITDA) increased, its margins contracted.
Rossari Biotech's net profit was up 3.2% at ₹32.7 crore from ₹31.7 crore int he previous year.
Its revenue witnessed a 13.4% increase to ₹581.6 crore from ₹512.7 crore in the third quarter of the previous fiscal.
The company's EBITDA also increased 6.3% annually to ₹68.8 crore from ₹64.7 crore.
However, its margin contracted to 11.8% from 12.6% in the year-ago period.
Shares of Rossari Biotech ended the previous session nearly 1% lower at ₹534.5 apiece. The stock has declined 33.6% in the past year.
Also Read: Punjab & Sind Bank Q3 Results | Profit rises 19% YoY, asset quality improves
While its net profit, revenue and earnings before interest tax depreciation and amortisation (EBITDA) increased, its margins contracted.
Rossari Biotech's net profit was up 3.2% at ₹32.7 crore from ₹31.7 crore int he previous year.
Its revenue witnessed a 13.4% increase to ₹581.6 crore from ₹512.7 crore in the third quarter of the previous fiscal.
The company's EBITDA also increased 6.3% annually to ₹68.8 crore from ₹64.7 crore.
However, its margin contracted to 11.8% from 12.6% in the year-ago period.
Shares of Rossari Biotech ended the previous session nearly 1% lower at ₹534.5 apiece. The stock has declined 33.6% in the past year.
Also Read: Punjab & Sind Bank Q3 Results | Profit rises 19% YoY, asset quality improves
/images/ppid_59c68470-image-17685450389293444.webp)
/images/ppid_a911dc6a-image-17686340540981990.webp)
/images/ppid_a911dc6a-image-176856123233653956.webp)
/images/ppid_a911dc6a-image-17686317305728310.webp)
/images/ppid_59c68470-image-176837504658945007.webp)
